Related Experiment Videos
Low-dose cyclosporine A in severe psoriasis
1Department of Dermatology, University of Newcastle upon Tyne, UK.
Transplantation Proceedings
|June 1, 1988
Summary
Small doses of Cyclosporine A (CsA) effectively cleared psoriasis rash in a small trial. However, rapid relapse occurred upon cessation, and long-term use showed rising creatinine levels, potentially limiting its sustained efficacy.
Area of Science:
- Dermatology
- Immunology
- Nephrology
Background:
- Psoriasis is a chronic autoimmune skin condition.
- Long-standing, severe psoriasis presents significant treatment challenges.
- Cyclosporine A (CsA) is an immunosuppressant with potential dermatological applications.
Purpose of the Study:
- To evaluate the efficacy of low-dose Cyclosporine A (CsA) in treating severe, long-standing psoriasis.
- To assess the short-term and medium-term adverse effects of CsA in this patient cohort.
- To determine the durability of CsA's therapeutic effects and identify potential limitations for long-term use.
Main Methods:
- An open-label trial involving 12 patients with severe, long-standing psoriasis.
- Administration of Cyclosporine A (CsA) in small, unspecified doses.
- Monitoring of rash clearance, relapse rates after drug cessation, and serum creatinine levels over 36 to 84 weeks.
Main Results:
- Cyclosporine A (CsA) demonstrated high effectiveness in clearing psoriatic rash.
- Rapid relapse of psoriasis was observed in all patients after discontinuing CsA treatment.
- Five out of seven patients exhibited elevated serum creatinine levels between 36 and 84 weeks, indicating potential nephrotoxicity.
Conclusions:
- Low-dose Cyclosporine A (CsA) offers a potent, short-term treatment option for severe psoriasis.
- The rapid relapse rate necessitates continuous treatment or alternative strategies for sustained remission.
- Potential long-term nephrotoxicity associated with CsA use may restrict its prolonged application in managing psoriasis.